(Total Views: 497)
Posted On: 08/09/2021 4:52:34 PM
Post# of 154137
i think that's right. even the first approval (and revenue) will be huge for us. going from a pre-revenue biotech to a revenue generating company puts us in a different league altogether.
since most biotechs trade at 5-6X revenue, even if we only generated $1 billion in revenue initially (say, from HIV), we'd be looking at around $6 billion in market cap - which is 7X our current value. obviously the long-term should be substantially higher than that as we add other indications - but i will be extremely excited about that first approval.
it would seem to be a virtual lock with Recknor working on the BLA. at the very least, i think we get that done this year - although i realize we'll be at the mercy of the FDA's response time.
since most biotechs trade at 5-6X revenue, even if we only generated $1 billion in revenue initially (say, from HIV), we'd be looking at around $6 billion in market cap - which is 7X our current value. obviously the long-term should be substantially higher than that as we add other indications - but i will be extremely excited about that first approval.
it would seem to be a virtual lock with Recknor working on the BLA. at the very least, i think we get that done this year - although i realize we'll be at the mercy of the FDA's response time.
(7)
(0)
